Comparison of antigen- and RT-PCR-based testing strategies for detection of Sars-Cov-2 in two high-exposure settings

3 Jay Love¹, Megan T. Wimmer², Damon J.A. Toth¹, Arthi Chandran², Dilip Makhija², Charles K.

4 Cooper², Matthew H. Samore¹, Lindsay T. Keegan¹

5 Affiliations: ¹University of Utah; ²Becton, Dickinson, and Company

6 Abstract

7 Surveillance testing for infectious disease is an important tool to combat disease transmission at

8 the population level. During the SARS-CoV-2 pandemic, RT-PCR tests have been considered

9 the gold standard due to their high sensitivity and specificity. However, RT-PCR tests for SARS-

10 CoV-2 have been shown to return positive results when administered to individuals who are past

11 the infectious stage of the disease. Meanwhile, antigen-based tests are often treated as a less

12 accurate substitute for RT-PCR, however, new evidence suggests they may better reflect

13 infectiousness. Consequently, the two test types may each be most optimally deployed in

14 different settings. Here, we present an epidemiological model with surveillance testing and

15 coordinated isolation in two congregate living settings (a nursing home and a university

16 dormitory system) that considers test metrics with respect to viral culture, a proxy for

17 infectiousness. Simulations show that antigen-based surveillance testing coupled with isolation

18 greatly reduces disease burden and carries a lower economic cost than RT-PCR-based strategies.

19 Antigen and RT-PCR tests perform different functions toward the goal of reducing infectious

20 disease burden and should be used accordingly.

21 Introduction

22 Since its emergence in late 2019, SARS-CoV-2, the virus responsible for COVID-19, has spread

23 rapidly, causing significant global morbidity and mortality. Although early outbreaks were

24 concentrated in China and Italy, the United States (US) was the global epicenter for most of

25 2020, accounting for approximately one fourth of all cases globally by March 2021 (Dong, Du,

26 & Gardner, 2020). Despite the approval of multiple SARS-CoV-2 vaccines, production,

27 distribution, and uptake hurdles combined with the emergence of novel viral variants indicates

that achieving herd immunity remains a distant prospect (Moore & Offit, 2021; Sallam, 2021).

29 Therefore, comprehensive testing, contact tracing, and infectious case isolation remain important

30 interventions to continue slowing the spread of SARS-CoV-2 and maintaining health system

31 integrity (Love et al., 2021).

32 As testing availability has increased, epidemiological questions have arisen regarding the optimal

33 deployment of different test strategies. Diagnostic tests for SARS-CoV-2, none of which

34 perfectly reflect viral carriage (Woloshin et al. 2020), fall into two broad categories: antigen tests

35 and real-time reverse transcription polymerase chain reaction (RT-PCR) tests. While both tests

36 diagnose active SARS-CoV-2 infection, antigen tests detect the presence of a specific viral

antigen and are capable of returning results within 15 minutes, while RT-PCR amplify genomic

38 sequences and therefore require longer turn-around times (CDC 2021a). Substantial attention has

39 been paid to the lower sensitivity of antigen testing compared with that of RT-PCR testing

- 40 (Scohy et al., 2020). Early studies on SARS-CoV-2 antigen testing sensitivity reported relatively
- 41 low sensitivity with respect to RT-PCR, leading some public health officials to place lower
- 42 confidence in antigen testing than RT-PCR testing in ending the COVID-19 pandemic. However,
- 43 it has been suggested that when comparing antigen- and RT-PCR tests to viral culture, a proxy
- 44 for transmissibility, one rapid antigen test (Becton Dickinson Veritor) had a negative percent
- 45 agreement of 96.4% (95% CI: 82.3, 99.4) and a positive percent agreement of 90.0% (CI: 76.3,
- 46 97.6), while positive percent agreement for the RT-PCR assay was 73.7% (CI: 60.8, 85.3)
- 47 (Pekosz et al., 2021). These studies suggest that antigen tests may perform better than RT-PCR
 48 tests at detecting actively infectious infections, since RT-PCR tests may detect low levels of viral
- tests at detecting actively infectious infections, since RT-PCR tests may detect low levels of viral
 nucleic acid that may not indicate current infectiousness (CDC 2020a). Consequently, the two
- 50 different test types may have different optimal strategies for deployment. The more rapid antigen
- 50 tests may be more optimally deployed when a delay in test results will delay the isolation of an
- 52 infectious infection (e.g., Larremore et al., 2021), while RT-PCR tests may be more optimally
- 53 deployed when diagnosing every infection or disease case is critical (e.g., Wang et al., 2020).
- 54 Recent studies have demonstrated that regardless of test sensitivity, widespread, high-frequency
- testing is sufficient to significantly reduce the burden of COVID-19 (Larremore et al., 2021;
- 56 Mina, Parker, & Larremore, 2020; Paltiel, Zheng, & Walensky, 2020). While this finding
- 57 highlights the importance of surveillance testing, it does not provide an explicit decision-support
- 58 framework for clinical and public health decisionmakers for testing strategies in congregate
- 59 settings. Building on such past work, we investigate the population-level epidemiological effects
- 60 of employing different COVID-19 surveillance testing strategies, including RT-PCR, antigen,
- 61 and two reflex testing strategies, in two non-acute care congregate living settings that bookend
- 62 the risk spectrum: a nursing home and a university residence hall system.
- 63
- 64 Methods
- 65 Epidemiological model
- 66 The epidemiological model is comprised of a dynamical model of SARS-CoV-2 with a layered
- 67 statistical model of hospitalizations, ICU hospitalizations, and deaths.

68 Transmission dynamics model

- 69 We developed a compartmental model of SARS-CoV-2 transmission dynamics with surveillance
- 70 testing by modifying a *Susceptible-Exposed-Infectious-Removed* (SEIR) model and including
- 71 individual-based accounting of infectious state (Figure 1). There are two simultaneous processes
- in the model: the disease process and the testing process. In the disease process (Figure 1),
- 73 individuals start as fully susceptible (S) and become exposed (E) according to a density-
- 74 dependent probability of exposure. This probability is defined as the product of a rate β and the
- 75 infectious proportion of the population, accounting for quarantine and isolation, as described
- 76 below (see Equation S1). The value of β is derived from the product of R₀, which we assume to
- be uniformly distributed between 1.2 and 1.5 (Zhang, Keegan, Qiu, & Samore, 2020), and the
- recovery rate, γ , which we assume to be uniformly distributed between 1/2.6 and 1/6 per day

79 (Lin et al., 2020). Exposed individuals have had a successful exposure event but are not yet

- 80 infectious; they become infectious (I) at a rate σ and are then able to infect others. We assume σ
- is 1/3 (Peirlinck, Linka, Sahli Costabal, & Kuhl, 2020). Infected individuals are 81
- 82 removed/recover (R) at a rate γ . The removed/recovered compartment indicates individuals who
- are no longer infectious, which includes both recovered and dead individuals; we use the classic 83
- 84 epidemiologic definition of this term, and do not use it to refer to a clinical recovery. We seed
- our simulations based on a prevalence of 1.8% in the residence hall setting and 3.6% in the 85
- 86 nursing home setting.
- 87 In the testing process (Figure 1), we assume a fixed proportion of the population, τ , is tested each
- day (surveillance testing). The assumptions and parameter values for our baseline simulation 88 settings are as follow (Table S1). We assume that susceptible individuals who test positive ($T_{S_{1}}$ 89
- 90 false positive) do so at a rate of $\phi_a = 0.0001$ to account for imperfect test specificity. For tested
- exposed (T_E) and tested recovered (T_R) individuals, we use the negative percent agreement of 91
- 92 each test compared to culture reported in published analyses for RT-PCR ($\phi_p = 95.5\%$) and for
- 93
- antigen tests ($\phi_p = 98.7\%$) (Pekosz et al., 2021). For tested infectious individuals (T_l), we use the
- 94 antigen test positive percent agreement $\phi_e = 96.4\%$ and RT-PCR positive percent agreement
- 95 $\phi_e = 100\%$ reported in the same analysis (Pekosz et al., 2021). We assume that individuals who
- test positive are isolated (Q) and are returned from isolation after an average of 14 days ($\omega =$ 96
- 0.07 in figure 1, though return from isolation is determined as $1/\omega$ days after the start of 97
- 98 isolation; see below); we also explore a shorter 10-day isolation (see supplement). We assume
- 99 that patients will reduce their mixing while awaiting test results and therefore are both less
- 100 susceptible and less infectious. As a baseline assumption, we use a 50% reduction in mixing due
- to this partial quarantine (q). We also explore two additional possible reductions of 25% and 101





- 103 disease course as normal. Test results for antigen testing are returned on the same day as test
- 104 administration ($\theta = 1$), while results are returned in 48 hours for RT-PCR ($\theta = 1/3$), an
- 105 approximation for the US average time for RT-PCR test result turnaround (as in Larremore et al.,

- 2021). We explore two additional possible RT-PCR test turnaround times of 1 and 4 days in thesupplement.
- 108 Figure 1. Schematic of the COVID-19 epidemiologic model. Individuals in the population 109 start as susceptible (S) and become exposed (E) at a rate β . Exposed individuals become 110 infectious (I) at a rate σ , and recover (R) at a rate γ . Simultaneously, surveillance testing occurs 111 at a rate proportional to the population make up, and individuals awaiting test results are in a "leaky" quarantine. Tested susceptibles (T_S) can become exposed (T_E) , then infectious (T_I) , and 112 113 can infect susceptibles (both S and T_S). Since tested infectious individuals (T_I) are quarantining, 114 their infectiousness is reduced by a factor q. Likewise, since tested susceptibles (T_{δ}) , are also 115 quarantining, their susceptibility is reduced by a factor q. Individuals who test positive are 116 isolated (Q). We assume isolation is perfect, and thus individuals can only progress through their 117 disease process $(Q_E \rightarrow Q_I \rightarrow Q_R)$; susceptibles who are isolated cannot become infected and 118 infected individuals who are isolated cannot cause infections. After the isolation period is over 119 (14 days in the standard condition), individuals are returned to the general population, retaining 120 their current disease state. Antigen and RT-PCR tests have a specified positive (ϕ_{e}) and negative 121 percent agreement (ϕ_p) with viral culture (see text). ϕ_a is 0.0001, representing imperfect test 122 specificity. Note that we use positive percent agreement for tests of infectious individuals (1) and 123 negative percent agreement for both exposed (E) and recovered (R) individuals, as it has been 124 shown that RT-PCR may detect infection among individuals who are no longer infectious 125 (Kohmer et al., 2021). Here, the color and line-type of the arrows indicate whether or not the test 126 was "correct" or "incorrect" with respect to infectiousness, with dotted lines indicating incorrect
- 127 test results (i.e., false negative or false positive), red lines indicating a positive test, blue lines
- 128 indicating a negative test, black lines indicating that no test result was returned.
- 129 We assume isolation resulting from a positive test result is perfect, and thus individuals can only
- 130 progress through their disease process ($Q_E \rightarrow Q_I \rightarrow Q_R$); susceptibles who are isolated cannot
- 131 become infected and infected individuals who are isolated cannot cause infections. After the
- 132 isolation period is over (14 days in the standard condition), individuals are returned to the
- 133 general population, retaining their current disease state.

134 Test Settings

- 135 We selected two settings to bookend the risk spectrum for communal living scenarios: a nursing
- 136 home, where disease outcomes are more severe, and a university residence hall system, where
- 137 disease outcomes are less severe. In the nursing home setting, the population was 101,
- 138 hospitalization rate was 25% of infections, ICU admission rate was 35.3% of hospitalizations,
- and the fatality rate was 5.4% of total infections. In the residence hall system setting, the
- 140 population was 3150, hospitalization rate was 3.9% of infections, ICU admission rate was 23.8%
- 141 of hospitalizations, and the fatality rate was 0.01% of total infections (values reflect estimates
- 142 from CDC pandemic planning scenarios and expert guidance; CDC 2020b).

143 Testing strategies

- 144 We explore five testing strategies for each of these two settings and assumed asymptomatic
- screening of 1%, 2%, 5%, and 10% of the population each day. In each setting and for each

146 testing strategy, we ran the simulation for a duration of 183 days. The five testing strategies are 147 as follows:

- 148 1. Test once with RT-PCR test ("stand-alone PCR")
- 149 2. Test once with antigen test ("stand-alone antigen")
- 150
 3. Test once with antigen test, then retest all negative results with antigen test two days later
 ("reflex to antigen")
- Test once with antigen test, then retest all symptomatic negative results with RT-PCR test
 ("reflex symptomatic to PCR")
- 154 5. No surveillance testing ("no testing")
- 155 Testing strategy 4 relies on symptom presentation to flag symptomatic individuals with negative
- antigen tests for retesting. We assume that 60% of all infections are symptomatic (CDC 2020b).
- 157 To account for the potential influence of other circulating respiratory infections, we also assume
- a background rate of 2% of the population expressing symptoms of influenza-like illness that are
- unrelated to but could be confused with infection with SARS-CoV-2 (Tokarz et al., 2019; CDC
- 160 2021b). Individuals expressing influenza-like illness symptoms are randomly drawn from the
- 161 population each day with a 2% probability. Individuals expressing symptoms of COVID-19 or
- 162 influenza-like illness are flagged for retesting with RT-PCR in this strategy. Those individuals
- 163 flagged for retesting are quarantined in the same way as individuals awaiting test results.
- 164 To determine the relative impact of different testing strategies on the disease course, we compare
- a suite of metrics between the four testing strategies and against the output of the model in the
- absence of testing. The metrics reported are number of infections averted, hospitalizations
- 167 averted, deaths averted, and the per test reduction in infections.
- 168 Since using testing metrics with respect to viral culture as a proxy for infectiousness is a novel
- approach to modeling infectious disease surveillance testing strategy effectiveness, we also
- 170 conducted simulations using antigen test sensitivity and specificity with respect to RT-PCR test
- results. RT-PCR is capable of detecting levels of viral RNA that do not indicate infectiousness (i.e., "recovered" in our model) (Mina et al., 2020). While our main simulations use test positiv
- (i.e., "recovered" in our model) (Mina et al., 2020). While our main simulations use test positive
 percent agreement to determine test results exclusively for infectious individuals, in these
- alternate simulations, we use test sensitivity to determine test results for both infectious and
- recovered individuals less than 54 days after recovery, approximating the median duration of
- 176 RT-PCR detectable viral shedding in one analysis of 36 patients (Li, Wang, & Lv, 2020). We use
- 177 test specificity to determine test results for susceptible and exposed classes and recovered
- 178 individuals more than 54 days after recovery in these alternate simulations. Test sensitivity and
- 179 specificity are positive percent agreement with RT-PCR results, considered the testing standard.
- 180 Therefore, RT-PCR sensitivity and specificity are 100%, whereas antigen test sensitivity was
- 181 84.7% and specificity was 99.5%, following published results (Young et al. 2021).
- 182 We constructed the model in the R statistical environment (R Core Team, 2017). The discrete-
- 183 time model includes flows between states that are determined by rates at the population level and
- 184 by functions at the individual-level. The time step is one day. The probability of exposure is
- 185 frequency dependent and varies at each time step and across individuals. It is the product of the
- 186 infected and unquarantined proportion of the population at each time step and β plus the product

- 187 of the infected and quarantined proportion, the mixing rate reduction due to quarantine (q),
- 188 and β . β is determined by the product of random draws from uniformly-distributed values of *R0*
- and γ . The probability of becoming infectious is determined by the rate σ . Recovery, however, is
- 190 modeled not with a population-level rate (γ), but with an individual-based approach using a fixed
- 191 duration of infectiousness; for each infection, a recovery day is designated that is $1/\gamma$ time steps
- 192 from the day of infection. Similarly, tests are returned by defining a day of test return for each
- 193 test that is $1/\theta$ time steps from the day of testing, and return from isolation is determined by
- 194 defining an end day to the isolation period as $1/\omega$ days after isolation begins.
- 195 We conducted 10,000 stochastic simulations for each testing strategy in each setting.

196 <u>Economic Model</u>

- 197 To improve the decision support aspect of our model, we layered a cost effectiveness analysis on
- 198 top of the epidemiological model to estimate the costs of each testing strategy relative to the
- 199 relevant outcomes. We used parameter values estimated from literature sources and expert input
- 200 (Table S2). All costs were expressed in 2021 US dollars and are from the perspective of the
- 201 congregate setting decision makers. We estimated total testing and outcome costs per strategy
- and calculated Cost per Incremental Infection Avoided and Unnecessary Quarantine Costs. We
- also calculated Incremental Cost Effectiveness Ratios (ICER) to compare the four testing
- strategies with the no testing strategy using the following standard calculation: ICER = $\frac{\Delta costs}{\Delta costs}$.
- $\Delta outcome$

206 Testing Strategy Costs

207 We considered the direct cost of testing to be the product of the number of tests per day, price

- 208 per test per day, personal protective equipment (PPE) costs per day, and labor costs per day. For
- 209 each type of test, the total cost is the sum of these daily costs multiplied by the duration of the
- simulation. We assume that RT-PCR is sent to an external laboratory and therefore has no direct
- capital costs to the decision maker, and we assume PPE is the same for either type of testing. The
- 212 no test strategy by definition has no direct testing costs.

213 Outcomes Cost Model

We then consider the direct costs to the decision makers who purchase and conduct testing in each of our two settings: universities and nursing homes. For nursing homes, staff absenteeism due to quarantine incurs costs measured in labor productivity loss, a cost limited to staff, and a conservative proxy for true costs which could include temporary staff and other costs. Positive test results in either residents or staff incur labor costs for the administrative burden of reporting positives and initiating cleaning protocols. For positive residents, additional PPE and labor costs are incurred due to assumed need for isolation and additional staff care for those residents. Total

221 outcomes cost is therefore calculated as:

223
$$O_n costs = \left(\frac{labor cost}{I_{Res}} + \frac{cleaning/precautions}{I} + \frac{PPE cost}{Q_{Res}} + \frac{reporting cost}{I}\right) \cdot I$$
222

224 where

225
$$PPE \ cost = \left(glove \ cost \cdot \frac{gloves}{test} \cdot tests\right) + \left(\frac{masks}{day} \cdot mask \ cost\right)$$

226
$$+ \left(face shield cost \cdot \frac{face shields}{day}\right) + \left(\frac{gowns}{day} \cdot gown cost\right)$$

and where labor cost is the product of the hourly wage and the number of hours worked for eachhealthcare worker type.

- For university residence halls, the cost per infection $(O_n costs)$ was provided based on expert input.
- 231 See Table S2 for cost parameter values and references.

232 Results

233 Compared to simulations without testing, all testing strategies reduced the peak and total

234 infections in simulated epidemics (Figure 1). Greater reduction in infections was achieved with

235 higher rates of daily screening. The relative differences between testing strategies' performance

in reducing infections were largely maintained across both nursing home and dormitory settings.



Figure 2. Epidemic curves showing infections over time in the nursing home (left) and residence hall (right) group living settings and at 2% and 10% daily surveillance testing. Higher levels of testing reduce infections. Different test strategies perform similarly. Line color indicates testing strategy.

237 In the nursing home setting, no statistically significant differences were found in % infections

averted across testing strategies at low levels of surveillance testing (1%, 2%). At high levels of

- surveillance testing (5%, 10%), the reflex to antigen strategy (34% and 53% averted)
- 240 outperformed standalone PCR (26% and 44% averted), which outperformed standalone antigen
- 241 (20% and 35% averted) (Figures 2,3). The reflex symptomatic negatives to PCR strategy did not
- statistically significantly improve performance versus standalone antigen in any case (Figure 2).

243 These same broad trends were also observed in the university residence hall setting. For

- university dormitories under screening rates of 1%, the reflex to antigen strategy averted the
- highest percentage of infections ($\sim 6\%$), followed by standalone PCR ($\sim 5\%$), then standalone
- antigen (\sim 3%). Standalone antigen testing and reflexing symptomatic to PCR strategies were
- again statistically equivalent in infection reduction (~3%) (Figure 2). At higher daily screening
 rates, this overall pattern was largely conserved, yet exaggerated. For 5% and 10% daily testing,
- rates, this overall pattern was largely conserved, yet exaggerated. For 5% and 10% daily testing overall reduction of infection rates increased to 16-32%, and 34-64%, respectively (Figure 2).
- 250 Since hospitalizations and deaths are calculated as proportions of infections, hospitalizations
- averted and deaths averted follow patterns similar to that found in infections averted (Figure S1).
- 252 Very few deaths occurred in the residence hall setting.
- 253 On a per-test basis, different testing strategies resulted in similar percent infections averted

254 (Figure S8). At higher surveillance levels (i.e., 5% and 10% daily surveillance) and with larger

255 populations (i.e., in the residence hall setting), standalone PCR testing showed a notably higher

256 mean per-test percent infection averted (Figure S8).



Figure 3. Percent infections averted for different testing strategies at different daily surveillance testing percentages. Red = 10%, green = 5%, blue = 2%, black = 1% daily surveillance testing. Filled circles show means, whiskers show 95% CI. Text labels indicate values of upper and lower 95% confidence interval bounds.

- 257 Overall, surveillance testing reduces the disease burden in populations, and the effect of testing
- 258 on measures of disease burden was greatest at the highest rates of testing. We found similar
- 259 patterns in simulations that used different parameter values for days to PCR test return,
- 260 quarantine mixing reduction, and days of isolation (See Figures S2-S7).

261 When evaluating antigen testing by modeling test sensitivity and specificity with respect to PCR,

- we find that the performance difference between standalone antigen and PCR testing is greater
- than when these test features are modeled with respect to viral culture (Figure S2). For example,
- the difference between standalone PCR and antigen testing strategies in mean % infections
- averted in the residence hall setting at 10% daily surveillance testing was roughly 20% when
- evaluating test performance with respect to PCR (Figure S2b) but only roughly 15% when
- evaluating test performance with respect to viral culture (Figure 3).
- 268 The economic analysis revealed that antigen-based strategies carried an overall lower economic
- 269 cost than did RT-PCR-based strategies. At 2% and 10% screening rates, respectively, over the 6-
- 270 month period in nursing homes, the testing strategy of standalone antigen testing was least
- expensive in terms of overall testing costs overall testing costs (\$25,037 and \$48,445), total costs
- (\$38,250 and \$77,460) and testing cost per infection (\$544 and \$1,514) (Table 1). For university
 dormitories, a similar pattern was evident (testing costs \$486,074 and \$952,940, total costs
- dormitories, a similar pattern was evident (testing costs \$486,074 and \$952,940, total costs
 \$798,147 and \$1,445,972, testing cost per infection \$419 and \$840, at 5% and 10% screening per
- 6 months, respectively) (Table 1). The overall testing and total costs are higher for the university
- residence hall setting, reflecting the larger population and higher number of tests needed. In the
- residence hall setting, the cost per person is lower than that of the nursing home setting,
- 278 demonstrating efficiencies of scale.
- 279 Due to the low number of occurring retests, the reflex symptomatic to PCR strategy had costs
- very similar to standalone antigen testing (Table 1). Importantly, stand-alone PCR resulted in the
- 281 highest costs of all of the testing strategies.
- 282 Strategies that resulted in longer test result wait time increased unnecessary quarantine costs,
- 283 with stand-alone PCR resulting in the highest of these across settings at all screening rates,
- ranging from 1.61-2.34 times as costly as the testing strategy with the least unnecessary
- quarantine costs (Table 1). ICERs were calculated for all testing strategies. Antigen-based
- strategies averaged lower ICERs than PCR-based strategies (Table 1).
- 287

288 Discussion

- 289 Our model demonstrates that surveillance testing paired with quarantine and isolation is likely to
- reduce disease burden in congregate living settings during the COVID-19 pandemic. Higher
- rates of screening result in the strongest reduction in infections and are associated with greater
- 292 distinction between the performance of different testing strategies. At low screening rates, testing
- strategies performed similarly to each other. Despite differences in population size and
- underlying risk, both residence hall and nursing home settings showed reduced disease burden
- 295 with increased surveillance testing.
- 296 Notably, the degree to which the standalone PCR testing strategy prevents infections is highly
- 297 contingent on the effectiveness of quarantine during the test-result waiting period. At low
- 298 waiting-period quarantine effectiveness, standalone PCR testing outperforms standalone antigen
- testing to a lesser degree than at higher waiting-period quarantine effectiveness (Figures 2, 3, S6,

300 S7). If individuals awaiting surveillance test results do not undergo quarantine, as may occur in 301 some settings, the difference between these two testing strategies is likely to less pronounced.

302 While the reflex to antigen strategy was the most effective at reducing infections, standalone

303 antigen testing was the least expensive and most cost-effective testing strategy in both settings at

304 all screening rates, due primarily to differences in test prices. Standalone PCR testing performed

305 well, but it was outperformed by the reflex to antigen strategy, both in terms of economic cost

306 and of reducing disease burden.

307 During the COVID-19 pandemic, RT-PCR testing has been established as the standard by which 308 to measure other tests. Our modeling analysis demonstrates that using viral culture, which may

better reflect viral transmissibility (Pekosz et al., 2021), as the test standard dramatically alters

310 the relative performance of different surveillance testing strategies. Under this paradigm,

311 antigen-based surveillance testing strategies coupled with infectious case isolation are shown to

312 strongly reduce disease burden at a level close to RT-PCR-based strategies, but at a much lower

economic cost (Figures 2,3), somewhat in contrast to model results under a more typical RT-

314 PCR test-standard paradigm (Figure S2). This lower cost has the potential to make additional

315 resources available for other management, containment, or recovery efforts, and therefore has the

316 potential to substantially reduce disease burden during the COVID-19 pandemic or others in the

future. Understanding test results with the priority endpoint in mind (e.g., the test's ability to

318 identify currently infectious infections during surveillance testing programs) should be of

319 primary importance, and our modelling study should prompt further research on the relationship

320 between viral culture, diagnostic test results, and transmissibility for SARS-CoV-2 and other

321 infectious diseases.

322 The cost perspective of this model may be of use to public health decision makers in determining

323 whether or not to invest in surveillance testing, but it does not account for the broader costs to

324 society and the healthcare system. An expanded or alternative perspective to this model that

325 could estimate the indirect societal costs of infection, disease, and quarantine would likely yield

326 more robust cost-effectiveness values and ICERs compared to those we find here.

327 Our results support the work of other studies that demonstrate that frequency of testing can

328 overcome differences in sensitivity (e.g., Larremore et al. 2021). In an important addition, we

329 provide a pragmatic example of an affordable and effective strategy that is implementable in two

330 group-living settings. As vaccine uptake remains low in many group living settings (e.g.,

331 Cavanaugh et al. 2021), and as a greater understanding of the potential for immune escape

332 mutants is developed (Garcia-Beltran et al., 2021), surveillance testing strategies that use antigen

tests can be considered as highly effective, cost-reducing alternatives to PCR testing strategies.

334 References

335 Cavanaugh, A. M., Fortier, S., Lewis, P., Arora, V., Johnson, M., George, K., Tobias, J., Lunn,

336 S., Miller, T., Thoroughman, D., & Spicer, K. B. (2021). COVID-19 Outbreak Associated

337 with a SARS-CoV-2 R.1 Lineage Variant in a Skilled Nursing Facility After Vaccination

338 Program - Kentucky, March 2021. MMWR. Morbidity and Mortality Weekly Report, 70(17),

339 639–643. doi:10.15585/mmwr.mm7017e2

- CDC (2021a). Overview of Testing for SARS-CoV-2 (COVID-19). March 17, 2021.
- https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html (accessed March
 17, 2021).
- 343 CDC (2021b) FLUVIEW: U.S. Influenza Surveillance System. October 6, 2020.
- 344 https://www.cdc.gov/flu/weekly/overview.htm (accessed June 1, 2021).
- 345 CDC (2020a) Interim Guidance for Antigen Testing for Sars-Cov-2.
- https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antigen-tests-guidelines.html
 (accessed March 17, 2021).
- 348 CDC (2020b) COVID-19 Pandemic Planning Scenarios. https://www.cdc.gov/coronavirus/2019 349 ncov/hcp/planning-scenarios.html (accessed March 17th, 2021)
- Dong, E., Du, H., & Gardner, L. (2020). An interactive web-based dashboard to track COVID-19
 in real time. *The Lancet Infectious Diseases*, 20(5), 533–534.
 https://doi.org/10.1016/S1473-3099(20)30120-1
- Garcia-Beltran, W. F., Lam, E. C., St. Denis, K., Nitido, A. D., Garcia, Z. H., Hauser, B. M., ...
 Balazs, A. B. (2021). Circulating SARS-CoV-2 variants escape neutralization by vaccineinduced humoral immunity. *MedRxiv*, 2021.02.14.21251704.
 https://doi.org/10.1016/j.cell.2021.03.013
- Kohmer, N., Toptan, T., Pallas, C., Karaca, O., Pfeiffer, A., Westhaus, S., ... Rabenau, H. F.
 (2021). The Comparative Clinical Performance of Four SARS-CoV-2 Rapid Antigen Tests
 and Their Correlation to Infectivity In Vitro. *Journal of Clinical Medicine*, *10*(2), 328.
 https://doi.org/10.3390/jcm10020328
- Larremore, D. B., Wilder, B., Lester, E., Shehata, S., Burke, J. M., Hay, J. A., ... Parker, R.
 (2021). Test sensitivity is secondary to frequency and turnaround time for COVID-19
 screening. *Science Advances*, 7(1), 1–11. https://doi.org/10.1126/sciadv.abd5393
- Li, N., Wang, X., & Lv, T. (2020). Prolonged SARS-CoV-2 RNA shedding: Not a rare
 phenomenon. *Journal of Medical Virology*, *92*(11), 2286–2287.
 https://doi.org/10.1002/jmv.25952
- Lin, Q., Zhao, S., Gao, D., Lou, Y., Yang, S., Musa, S. S., ... He, D. (2020). A conceptual model
 for the coronavirus disease 2019 (COVID-19) outbreak in Wuhan, China with individual
 reaction and governmental action. *International Journal of Infectious Diseases*, 93, 211–
 216. https://doi.org/10.1016/j.ijid.2020.02.058
- Love, J., Keegan, L. T., Angulo, F. J., McLaughlin, J., Shea, K. M., Swerdlow, D. L., ... Toth,
 D. J. (2021). Continued need for non-pharmaceutical interventions after COVID-19
 vaccination in long-term- care facilities. *MedRxiv*.
 https://doi.org/10.1101/2021.01.06.21249339
- Mina, M. J., Parker, R., & Larremore, D. B. (2020). Rethinking Covid-19 Test Sensitivity A
 Strategy for Containment. *New England Journal of Medicine*, 383(22).
 https://doi.org/10.1056/NEJMp2025631
- Moore, J. P., & Offit, P. A. (2021). SARS-CoV-2 Vaccines and the Growing Threat of Viral
 Variants. *JAMA Journal of the American Medical Association*, 4399(August 2020), 2020–
 2021. https://doi.org/10.1001/jama.2021.1114
- 381 Paltiel, A. D., Zheng, A., & Walensky, R. P. (2020). Assessment of SARS-CoV-2 Screening

- 382 Strategies to Permit the Safe Reopening of College Campuses in the United States. JAMA 383 Network Open, 3(7), e2016818. https://doi.org/10.1001/jamanetworkopen.2020.16818
- 384 Peirlinck, M., Linka, K., Sahli Costabal, F., & Kuhl, E. (2020). Outbreak dynamics of COVID-385 19 in China and the United States. *Biomechanics and Modeling in Mechanobiology*, 19(6),
- 386 2179-2193. https://doi.org/10.1007/s10237-020-01332-5
- 387 Pekosz, A., Parvu, V., Li, M., Andrews, J. C., Manabe, Y. C., Kodsi, S., ... Cooper, C. K. 388 (2021). Antigen-Based Testing but Not Real-Time Polymerase Chain Reaction Correlates 389 With Severe Acute Respiratory Syndrome Coronavirus 2 Viral Culture. Clinical Infectious 390 Diseases, 21205(Xx), 1-6. https://doi.org/10.1093/cid/ciaa1706
- 391 R Core Team. (2017). R: A language and environment for statistical computing. Vienna, Austria: 392 R Foundation for Statistical Computing.
- 393 Sallam, M. (2021). COVID-19 Vaccine Hesitancy Worldwide: A Concise Systematic Review of 394 Vaccine Acceptance Rates. Vaccines, 9(2), 160.
- 395 Scohy, A., Anantharajah, A., Bodéus, M., Kabamba-Mukadi, B., Verroken, A., & Rodriguez-396 Villalobos, H. (2020). Low performance of rapid antigen detection test as frontline testing 397 for COVID-19 diagnosis. Journal of Clinical Virology, 129(May), 104455.
- 398 https://doi.org/10.1016/j.jcv.2020.104455
- 399 Tokars, J. I., Olsen, S. J., & Reed, C. (2018). Seasonal Incidence of Symptomatic Influenza in 400 the United States. Clinical Infectious Diseases, 66(10), 1511–1518. 401 https://doi.org/10.1093/cid/cix1060
- 402 Wang, Y., Kang, H., Liu, X., & Tong, Z. (2020). Combination of RT-qPCR testing and clinical 403 features for diagnosis of COVID-19 facilitates management of SARS-CoV-2 outbreak. 404 Journal of Medical Virology, 92(6), 538–539. https://doi.org/10.1002/jmv.25721
- 405 Woloshin, S., Patel, N., & Kesselheim, A. S. (2020). False Negative Tests for SARS-CoV-2 406 Infection — Challenges and Implications. New England Journal of Medicine, 383(e83). 407 doi:10.1056/NEJMp2015897
- 408 Young, S., Taylor, S. N., Cammarata, C. L., Roger-Dalbert, C., Montano, A., Griego-Fullbright,
- 409 C., Burgard, C., Fernandez, C., Eckert, K., Andrews, J. C., Ren, H., Allen, J., Ackerman, R.,
- 410 Gary, D., & Cooper, C. K. (2021). Clinical evaluation of BD Veritor SARS-CoV-2 point-
- 411 of-care test performance compared to PCR-based testing and versus the Sofia 2 SARS antigen point-of-care test. Journal of Clinical Microbiology, 59(1), 02338-20.
- 412
- 413 https://doi.org/10.1128/JCM.02338-20
- 414 Zhang, Y., Keegan, L. T., Qiu, Y., & Samore, M. H. (2020). The real time effective reproductive 415 number for COVID-19 in the United States. MedRxiv, 10-13.
- 416 https://doi.org/10.1101/2020.05.08.20095703
- 417
- 418
- 419
- 420

Surveillance	d Sivitingi hich was n	nt doi <mark>ot ce</mark>	: https://pigrg/fipal/tegry202 rtified by peer review) is th	1.00.03.01125824	8; Tristydreigsting ted J who has granted medR	lune red for the second s	igh Peologe for thi s pre the preprint in perpetu	prinCost per
%0			It is made ava	illabf@&hd&&& CC infection	C-BY-NCCNST4.0 Interna	ational license .	testing cost	infection
								avoided
10/	NILL	1	DCD		* 21 (52 (0)	<i></i>	¢10.05	¢10.040.55
1%	NH	1	PCR	\$659.40	\$31,652.69	\$43,324.77	\$10.05	\$12,840.77
	NH	2	Antigen	\$459.99	\$22,125.35	\$29,174.74	\$7.02	\$9,007.33
	NH	3	with antigen	\$539.16	\$24,959.52	\$35,762.94	\$7.92	\$6,012.60
	NH	4	retest negative symptomatic PCR	\$471.29	\$22,167.77	\$29,708.94	\$7.04	\$6,707.82
	NH	5	None					
	Dorms	1	PCR	\$298.35	\$485,242.81	\$609,273.18	\$154.05	\$4,043.76
	Dorms	2	Antigen	\$68.10	\$112,601.12	\$184,479.47	\$35.75	\$1,485.94
	Dorms	3	retest all negatives with antigen	\$126.32	\$202,452.15	\$348,270.93	\$64.27	\$1,714.37
	Dorms	4	retest negative symptomatic PCR	\$67.97	\$112,599.40	\$185,112.30	\$35.75	\$1,521.70
	Dorms	5	None					
2%	NH	1	PCR	\$1,063.56	\$46,654.07	\$67,441.43	\$14.81	\$7,461.16
	NH	2	antigen	\$544.68	\$25,037.09	\$38,250.02	\$7.95	\$5,331.76
	NH	3	retest all negatives with antigen	\$703.20	\$30,636.99	\$49,059.50	\$9.73	\$4,538.34
	NH	4	retest negative symptomatic PCR	\$551.15	\$25,109.82	\$38,597.40	\$7.97	\$5,058.64
	NH	5	None					
	Dorms	1	PCR	\$622.28	\$953,359.76	\$1,182,796.20	\$302.65	\$3,926.41
	Dorms	2	antigen	\$128.87	\$205,871.92	\$344,489.52	\$65.36	\$1,432.23
	Dorms	3	retest all negatives with antigen	\$257.34	\$384,030.53	\$652,701.97	\$121.91	\$1,667.43
	Dorms	4	retest negative symptomatic PCR	\$128.84	\$206,013.34	\$345,351.85	\$65.40	\$1,440.51
	Dorms	5	None					
5%	NH	1	PCR	\$3,066.44	\$91,330.75	\$129,235.64	\$913.31	\$6,569.19
	NH	2	antigen	\$1,063.42	\$33,839.19	\$59,210.23	\$338.39	\$3,357.35
	NH	3	retest all negatives with antigen	\$1,987.85	\$47,376.39	\$76,359.32	\$473.76	\$2,979.99
	NH	4	retest negative symptomatic PCR	\$1,030.46	\$33,973.28	\$60,181.84	\$339.73	\$3,650.04
	NH	5	none					

	Dorms	1	PCR	\$2,263.99	\$2,359,441.85	\$2,808,400.54	\$749.03	\$4,205.48
	Dorms	2	antigen	\$418.97	\$486,074.53	\$798,147.93	\$154.31	\$1,451.72
	Dorms	3	retest all negatives with antigen	\$1,088.13	\$919,568.27	\$1,425,698.88	\$291.93	\$1,648.46
	Dorms	4	retest negative symptomatic PCR	\$419.71	\$486,327.46	\$797,692.80	\$154.39	\$1,447.13
	Dorms	5	none					
10%	NH	1	PCR	\$5,981.02	\$165,931.49	\$210,071.39	\$1,659.31	\$6,880.82
	NH	2	antigen	\$1,514.33	\$48,445.07	\$77,460.72	\$484.45	\$2,695.88
	NH	3	retest all negatives with antigen	\$3,199.94	\$74,309.03	\$102,585.67	\$743.09	\$2,777.84
	NH	4	retest negative symptomatic PCR	\$1,556.56	\$48,636.12	\$77,438.30	\$486.36	\$2,636.02
	NH	5	none					
	Dorms	1	PCR	\$5,427.84	\$4,700,756.49	\$5,260,632.24	\$1,492.30	\$4,680.53
	Dorms	2	antigen	\$839.73	\$952,940.34	\$1,445,972.64	\$302.52	\$1,484.75
	Dorms	3	retest all negatives with antigen	\$2,864.65	\$1,779,042.18	\$2,312,562.13	\$564.78	\$1,677.51
	Dorms	4	retest negative symptomatic PCR	\$842.05	\$953,376.96	\$1,444,826.84	\$302.66	\$1,480.44
	Dorms	5	none					
	-							

421

Table 1. Results of the economic cost analysis. In both settings and at all levels of surveillance testing, the antigen-based testing strategy was least expensive. The "retest all negatives with antigen" strategy, which averted the most infections (Figure 3), was less expensive than PCR-based testing. The "retest negative symptomatic with PCR" strategy was similar in costs to the antigen-based testing strategy.